Metronome LLC v. Dermaquest LLC — Cannabis Topical Patent Suit Dismissed in 31 Days
Metronome LLC filed an infringement action in Delaware against Dermaquest LLC asserting US9095563B2, a patent covering topical treatments incorporating Cannabis sp. derived botanical drug products. The case ended just 31 days after filing when Metronome voluntarily dismissed without prejudice before Dermaquest had answered the complaint.
Cannabis topical patent suit ends at the starting line in Delaware
On 7 March 2025, Metronome LLC filed a patent infringement action in the District of Delaware against Dermaquest LLC, a topical skincare company. The asserted patent, US9095563B2 (application no. US14/498555), covers topical treatments incorporating Cannabis sp. derived botanical drug products — a commercially active area as CBD and cannabis-derived formulations have proliferated across the personal care and pharmaceutical markets.
Just 31 days after filing, on 7 April 2025, Metronome invoked Federal Rule of Civil Procedure 41(a)(1)(A)(i) to voluntarily dismiss the action without prejudice. Because Dermaquest had not yet filed an answer or moved for summary judgment, Metronome was entitled to dismiss as of right, requiring no court order. The without-prejudice designation means Metronome is not barred from refiling substantially the same claims against Dermaquest in the future.
A 31-day lifecycle — from filing to dismissal before any responsive pleading — is notably short even for early-exit patent cases. This pattern is consistent with several scenarios: the parties may have reached a confidential licensing or settlement arrangement, Metronome may have identified a deficiency in its infringement read and chosen to pause, or the filing may have been tactical. The public record does not disclose any settlement terms, licence, or stated reason for the dismissal.
Filing to Voluntary dismissal in 31 days
31 days — resolved before defendant answered, well under the median district court patent case duration
Voluntarily dismissed: what the without-prejudice exit means for both parties
Rule 41(a)(1)(A)(i): dismissal as of right, no court order needed
Federal Rule of Civil Procedure 41(a)(1)(A)(i) allows a plaintiff to dismiss an action without a court order at any time before the defendant serves an answer or a motion for summary judgment. Because Dermaquest had taken neither step, Metronome had an unconditional right to exit. The dismissal is self-executing upon filing of the notice — the court played no adjudicative role.
Pre-answer voluntary exitWithout prejudice confirmed — but the distinction matters
The notice expressly states the dismissal is without prejudice, meaning Metronome retains the right to refile the same infringement claims against Dermaquest in the future, subject to applicable statutes of limitations. A with-prejudice dismissal would have permanently extinguished those claims. The public record does not disclose whether any side agreement — such as a licence or covenant not to sue — accompanies this dismissal and effectively renders refiling unlikely.
Refiling rights preservedDermaquest exits without admission — but infringement cloud remains
Dermaquest faces no adverse judgment, injunction, or damages award. It incurred no obligation to answer the complaint. However, without prejudice dismissal provides no finality: Dermaquest has not obtained a covenant not to sue or a validity ruling. The infringement allegation over its cannabis-derived topical products remains legally unresolved, and the same patent could be reasserted if Metronome chooses to refile.
No judgment; cloud persistsCannabis topical IP enforcement: a warning shot regardless of outcome
The filing alone signals that US9095563B2 is being actively monitored and enforced by Metronome. Other companies commercialising cannabis-derived topical formulations — whether positioned as cosmetic, OTC drug, or dietary supplement products — should treat this case as a prompt to audit their freedom-to-operate position against this patent. A without-prejudice dismissal does not signal patent weakness; it preserves all enforcement options.
Active enforcement postureFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Metronome LLC | Company | Cannabis-derived topical drug product patent holder — asserting US9095563B2Search in Eureka ↗ |
| Defendant | Dermaquest, LLC | Company | Dermaquest LLC — topical skincare and treatment product companySearch in Eureka ↗ |
| Plaintiff counsel | Antranig N. Garibian | Attorney | Counsel for Metronome LLCSearch in Eureka ↗ |
| Plaintiff law firm | Garibian Law Offices, PC | Law Firm | Representing Metronome LLCSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and confirms Dermaquest had not answered or moved for summary judgment — the precise threshold that entitles a plaintiff to dismiss as of right. The explicit ‘without prejudice’ designation is legally significant: it forecloses any argument that the dismissal bars future litigation on the same claims. No merits adjudication occurred; no court ruling addresses the validity or infringement of US9095563B2.
US9095563B2 — Cannabis-derived botanical topical treatment patent
US9095563B2 (filed under application US14/498555) covers topical treatments incorporating Cannabis sp. derived botanical drug products. The patent sits at the intersection of pharmaceutical formulation and botanical drug regulation — a technically complex space where the FDA’s botanical drug guidance, DEA scheduling, and standard patent claim construction all interact. The granted patent number indicates it has cleared examination and is in force, giving Metronome an issued right to exclude.
As the cannabis-derived topical market has expanded — encompassing CBD-infused cosmetics, OTC drug candidates, and prescription botanical formulations — patents like US9095563B2 carry significant commercial weight. Any competitor formulating topical products that incorporate hemp- or cannabis-derived extracts as active or functional ingredients should treat this patent as a potential blocking right. The fact that Metronome filed an infringement action demonstrates active enforcement intent, regardless of how this particular case resolved.
Should your team run an FTO against US9095563B2?
If your company develops, manufactures, or distributes topical products — cosmetic, OTC drug, or otherwise — that incorporate Cannabis sp. derived botanical drug products, US9095563B2 is a live enforcement risk. This case confirms the patent is being monitored and asserted. Product teams launching or updating cannabis-derived topical lines should commission a freedom-to-operate analysis before commercialisation, not after receiving a demand letter.
PatSnap Eureka’s FTO Search Agent can map the independent and dependent claims of US9095563B2 against your product formulations, flag prior art that may inform a validity challenge, and surface the full prosecution history to identify potential claim construction arguments. Use Eureka to benchmark against related botanical drug patents and monitor Metronome’s broader portfolio for additional enforcement vectors.
Run a freedom-to-operate analysis on US9095563B2 to assess your product’s exposure
Run FTO in Eureka →Similar cannabis and botanical drug patent infringement cases in US courts
Cases involving cannabis-derived topical or botanical drug product patents filed in Delaware and other US district courts with comparable infringement claims and dismissal outcomes.
What this case signals for the cannabis-derived topical IP landscape
A 31-day lifespan and without-prejudice exit suggests strategic flexibility — not defeat — for the patent holder.
Without-prejudice exit preserves full enforcement leverage for Metronome
Rule 41(a)(1)(A)(i) dismissals before answer are the cleanest available exit for a plaintiff. Metronome sacrifices nothing substantively — no claim is adjudicated, no validity ruling is issued, and the patent remains intact. Companies in the cannabis topical sector should not interpret this dismissal as a signal that US9095563B2 is weak or unenforceable.
Pre-answer dismissals in patent cases often precede confidential resolution
When a patent infringement case closes within 31 days — before the defendant even answers — it frequently suggests the parties reached a private arrangement (licence, settlement, or covenant not to sue) that made continued litigation unnecessary. The public record here is silent on any such agreement, but the speed and clean exit are consistent with that pattern.
Metronome v Dermaquest — key questions answered
It means Metronome dismissed the infringement action voluntarily under Rule 41(a)(1)(A)(i) before Dermaquest answered. The without-prejudice designation preserves Metronome’s right to refile the same claims in the future. No court ruled on the merits, validity, or infringement of US9095563B2.
Yes. A without-prejudice dismissal under Rule 41(a)(1)(A)(i) does not bar refiling, subject to applicable statutes of limitations and any private agreements between the parties not reflected in the public record. Metronome retains full enforcement rights against Dermaquest on US9095563B2.
US9095563B2 covers topical treatments incorporating Cannabis sp. derived botanical drug products. It is an issued US patent, meaning it carries a presumption of validity. Any company formulating topicals with cannabis or hemp-derived actives should assess whether their products fall within the patent’s claims, given that Metronome has demonstrated active enforcement intent by filing this action.
The public record does not state a reason. Common explanations for pre-answer voluntary dismissals in patent cases include a confidential settlement or licensing agreement, a decision to recalibrate the infringement theory, or tactical repositioning. The 31-day timeline is consistent with parties reaching a private resolution, but this cannot be confirmed from available filings.
The case was assigned to Judge Colm F. Connolly in the United States District Court for the District of Delaware, Case No. 1:25-cv-00275. Judge Connolly is a prominent patent litigation judge in Delaware, one of the most active patent venues in the United States.
PatSnap Eureka searches patents and litigation data to answer instantly.